214 related articles for article (PubMed ID: 37873862)
1. Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity.
Onyido EK; James D; Garcia-Parra J; Sinfield J; Moberg A; Coombes Z; Worthington J; Williams N; Francis LW; Conlan RS; Gonzalez D
Antibodies (Basel); 2023 Oct; 12(4):. PubMed ID: 37873862
[TBL] [Abstract][Full Text] [Related]
2. A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development.
Healey GD; Frostell A; Fagge T; Gonzalez D; Conlan RS
Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544813
[TBL] [Abstract][Full Text] [Related]
3. Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.
Lakayan D; Haselberg R; Gahoual R; Somsen GW; Kool J
Anal Bioanal Chem; 2018 Dec; 410(30):7837-7848. PubMed ID: 30328504
[TBL] [Abstract][Full Text] [Related]
4. The target atlas for antibody-drug conjugates across solid cancers.
Fang J; Guo L; Zhang Y; Guo Q; Wang M; Wang X
Cancer Gene Ther; 2024 Feb; 31(2):273-284. PubMed ID: 38129681
[TBL] [Abstract][Full Text] [Related]
5. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
[TBL] [Abstract][Full Text] [Related]
6. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
10. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.
Hammood M; Craig AW; Leyton JV
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358100
[TBL] [Abstract][Full Text] [Related]
11. The antibody-drug conjugate target landscape across a broad range of tumour types.
Moek KL; de Groot DJA; de Vries EGE; Fehrmann RSN
Ann Oncol; 2017 Dec; 28(12):3083-3091. PubMed ID: 29045509
[TBL] [Abstract][Full Text] [Related]
12. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
13. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
15. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
16. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.
Montero JC; Calvo-Jiménez E; Del Carmen S; Abad M; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Mar; 41(1):106. PubMed ID: 35317825
[TBL] [Abstract][Full Text] [Related]
17. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
18. Evolving Strategies for Target Selection for Antibody-Drug Conjugates.
Damelin M; Zhong W; Myers J; Sapra P
Pharm Res; 2015 Nov; 32(11):3494-507. PubMed ID: 25585957
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
